Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
Organizer:

Limited treatment options and sub-optimal formulations contribute to poor adherence and outcomes for children living with HIV and other diseases that affect the lives of children living in resource-limited settings. The Global Accelerator for Paediatric Formulations (GAP-f) aims to promote a faster, more efficient and more focused approach to paediatric formulation development. This session will present key principles for acceleration – and how these are brought together by the GAP-f – for different areas of the continuum, with a focus on: (1) prioritization and clinical research of priority formulations, (2) development and regulatory approval of paediatric drug formulations, and (3) uptake and procurement of optimal formulations for children. Panels will discuss (1) the value and opportunities for an integrated approach to paediatric medicines and (2) the business case and innovative funding. The session will end with an overview of what to watch in paediatric drug optimization.

Welcome
Sébastien Morin, International AIDS Society, Switzerland
10:15
Introduction: How can we accelerate the development and uptake of the most needed drug formulations for children?
Chip Lyons, Elizabeth Glaser Pediatric AIDS Foundation, United States
Linda-Gail Bekker, International AIDS Society, South Africa
10:25
Lived experience testimony: What non optimal paediatric drug formulations meant to me
Sharifah Kyomukama Nalugo, Stigmaless Uganda, Uganda
10:30
Acceleration part 1: Prioritization and clinical research of priority formulations
Elaine Abrams, The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, United States
Carlo Giaquinto, PENTA-Id Network, Italy
10:45
Acceleration part 2: Development and regulatory approval of paediatric drug formulations
Melynda Watkins, Clinton Health Access Initiative, United States
Fernando Pascual, Medicines Patent Pool, Spain
11:00
Acceleration part 3: Uptake and procurement of optimal formulations for children
Nandita Sugandhi, ICAP at Columbia University, United States
Jennifer Cohn, Elizabeth Glaser Pediatric AIDS Foundation, Switzerland
11:15
Q&A
Sébastien Morin, International AIDS Society, Switzerland
Sharifah Kyomukama Nalugo, Stigmaless Uganda, Uganda
Elaine Abrams, The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, United States
Carlo Giaquinto, PENTA-Id Network, Italy
Melynda Watkins, Clinton Health Access Initiative, United States
Fernando Pascual, Medicines Patent Pool, Switzerland
Nandita Sugandhi, ICAP at Columbia University, United States
Jennifer Cohn, Elizabeth Glaser Pediatric AIDS Foundation, Switzerland
11:25
Bringing it all together: The Global Accelerator for Paediatric Formulations (GAP-f)
Martina Penazzato, World Health Organization, Switzerland
Paul Domanico, Clinton Health Access Initiative, United States
11:40
Panel discussion: Moving beyond HIV and planning the next steps
Martina Penazzato, World Health Organization, Switzerland
Paul Domanico, Clinton Health Access Initiative, United States
Wiweka Kaszubska, Medicines for Malaria Venture, Switzerland
Isabelle Andrieux-Meyer, Drugs for Neglected Diseases initiative, Switzerland
George Siberry, The United States President’s Emergency Plan for AIDS Relief, United States
Robert Matiru, Unitaid, Switzerland
Taryn Barker, The Children's Investment Fund Foundation, United Kingdom
12:10
Summary and what to watch in paediatric drug optimization
Robert Matiru, Unitaid, Switzerland
Gottfried Hirnschall, World Health Organization, Switzerland